UK’s Competition Body Says Pharma Firms Can Work Together On Access To Combination Therapies
The UK’s Competition and Markets Authority will not prioritize the investigation of pharmaceutical companies that enter commercial negotiations with the aim of making combination therapies cost effective, a move that the ABPI says is an “international first”.
You may also be interested in...
NHS England has committed to two pilots on innovative pricing models for advanced therapies under the UK’s new voluntary pricing agreement for new medicines.
Indication-based pricing and tackling complications caused by competition law could help the UK catch up with other countries when it comes to market access for combination therapies.
HTA body NICE is exploring whether competition law impacts pricing of combination drugs in UK.